This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Horowitz, J. D. Articles by Louis, W. J. Search for Related Content PubMed PubMed Citation Articles by Horowitz, J. D. Articles by Louis, W. J.

Circulation, Vol 73, 987-996, Copyright © 1986 by American Heart Association

ARTICLES

Short-term myocardial uptake of lidocaine and mexiletine in patients with ischemic heart disease

JD Horowitz, MK Dynon, E Woodward, ST Sia, PS Macdonald, DJ Morgan, AJ Goble and WJ Louis

Determination of short-term myocardial drug uptake and subsequent redistribution was performed in 27 patients with ischemic heart disease for the antiarrhythmic agents lidocaine and mexiletine, using frequent simultaneous measurements of drug concentration in aortic and coronary sinus blood, combined with measurement of coronary sinus blood flow after intravenous bolus injection of the drug. Maximal myocardial drug content per unit resting coronary sinus blood flow (MDC:F) was significantly greater in patients in whom coronary sinus pacing at 100 beat/min was performed during the initial period of drug uptake. Maximal myocardial drug content occurred after 2.4 +/- 0.2 (SEM) for lidocaine and after 5.5 +/- 0.6 min for mexiletine (p less than .001), and pacing did not affect time to maximum myocardial drug content. In nonpaced, but not paced, patients maximal MDC:F was greater in the lidocaine group than that in the mexiletine group. The subsequent efflux of lidocaine from the myocardium was more rapid that that of mexiletine in both paced and nonpaced groups.

This article has been cited by other articles:

				C. J. Zeitz, D. J. Campbell, and J. D. Horowitz Myocardial Uptake and Biochemical and Hemodynamic Effects of ACE Inhibitors in Humans Hypertension, March 1, 2003; 41(3): 482 - 487. [Abstract] [Full Text] [PDF]